pe26 schreef op 29 oktober 2015 16:21:
Goede omzet voor Orkambi (double therapie: potentiator en 1 corrector) in Q3 2015 van Vertex, lancering product gedaan in Q3 2015.
De cijfers weerspiegelen de grootte van de CF-markt, waar Galapagos en AbbVie in toekomst ook belangrijke stappen kunnen gaan zetten. Sowieso is concurrentie goed, want Vertex heeft nu alleenrecht.
October 28, 2015
Vertex Reports Third Quarter 2015 Financial Results
-Third quarter 2015 revenues of $310 million, including net product revenues of $131 million for ORKAMBI® (lumacaftor/ivacaftor) and $166 million for KALYDECO® (ivacaftor) in cystic fibrosis--Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620 million-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2015. Vertex also increased its financial guidance for total 2015 KALYDECO® (ivacaftor) revenues and reiterated its prior guidance for non-GAAP operating expenses. Key financial results include:
"During the third quarter, more than 3,000 people started treatment with ORKAMBI in the U.S., underscoring the importance of this medicine to people with cystic fibrosis and their doctors and the interest to begin treatment as soon as possible," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Importantly, with the planned initiation of the first clinical study of a next-generation corrector this week, we continue to move quickly to develop combinations of our potential medicines that could provide enhanced benefit for people already taking our medicines and for others, to provide the first medicine to treat the underlying cause of their cystic fibrosis."
Op bijna 300 USD miljoen omzet toch nog 95 mln. verlies, maar die gaan hard slinken om omgezet worden in winsten.
Mag ook wel bij waardering + 25 miljard USD.